BRCA1 and cancer: Triple negative breast cancer caused by BRCA1 and BRCA2 mutation can be a potential target of DNA damaging chemotherapeutics and a number of clinical data leads to the suggestion that involving platinum-based chemotherapeutics may be use in standard treatment regime of early stage as well as advanced TNBC.4 As reported in earlier scientific research, platinum salts like cisplatin, carboplatin or oxaliplatin are able to initiate a platinum–DNA adduct formation followed by DNA damage in cancer cells leading towards apoptosis of the targeted cancer cells.